Sacituzumab Govitecan clinical trials
7 indexed studies · 5 currently recruiting
- RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
This study looks at a new combination treatment for advanced lung cancer. It compares giving a well-known drug (pembrolizumab) with or without an additional drug (sacituzumab govitecan) to see which is better at slowing the cancer's growth and helping people live longer.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Brazil - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metastatic esophagogastric adenocarcinoma
This study is testing a new medicine, Sacituzumab Govitecan, for people with advanced oesophageal or stomach cancer that has spread. It aims to see how well the medicine works by checking if tumours shrink. This is an early-stage study to learn more about this treatment.
For: metastatic esophagogastric adenocarcinoma (Stage IV)Germany · Austria - RecruitingPHASE3
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
This study is testing a new drug, sacituzumab govitecan, for people with an advanced type of breast cancer called triple-negative breast cancer. It's for those whose cancer has continued to grow after other treatments. The aim is to see how well it works and understand who it helps most.
For: Triple Negative Breast Cancer · Metastatic Breast CancerFrance - Not yet recruitingPHASE3
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
This study looks at new ways to treat a type of breast cancer called triple-negative early breast cancer. It compares a new drug combination with standard treatment to see if it works better at shrinking tumours before surgery and stopping cancer from coming back.
For: Breast Cancer · Triple-negative Breast CancerGermany - RecruitingPHASE2
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
This study looks at new ways to treat advanced breast cancer that has stopped responding to standard treatments. By checking your blood or tumour for specific signs, doctors hope to find the best treatment for you, exploring several new drugs and combinations.
For: Breast CancerCanada - RecruitingPHASE2
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
This study looks at how well a new treatment called sacituzumab govitecan (SG) works for advanced breast cancer after another treatment (T-DXd) has been used. We want to find clues in tumour samples to see who might benefit most from SG.
For: Breast CancerCanada